Distinguished Lecture Series: Therapeutic Targets and Therapeutic Agents for Neurodegeneration and Cancer-Dr. H. Uri Saragovi
Distinguished Lecture Series: Therapeutic Targets and Therapeutic Agents for Neurodegeneration and Cancer
Presented by: Dr. H. Uri Saragovi, Professor, McGill University, Lady Davis Institute-Jewish General Hospital
Dr. Saragovi has been recognized as a world-leading scientist in the area of Translational Medicine. In addition to highly referenced scientific Publications and 21 patents (most of which are licensed), he has also successfully translated drugs that were developed fully in his academic laboratory. His research focuses in understanding macromolecular structure function relationships, particularly in receptor-ligand interactions, in order to develop drug-like probes to validate molecular targets and to generate lead agents for therapy.
Using antibodies, mimetics, and small molecule ligands we carry out receptor biology and signal transduction studies. When justified, we develop second generation agents for evaluation in vivo in models of cancer or neurodegeneration (cognitive impairment in ageing, glaucoma, optic nerve axotomy, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, neurosensory hearing loss). Some agents have been successful in Phase 3 Clinical trials and others are at IND stage after having been validated in preclinical studies as safe and effective therapeutics.